上海莱士(002252) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥1,658,020,093.78, representing a 28.45% increase year-over-year[3] - Net profit attributable to shareholders was ¥542,739,578.90, an increase of 11.73% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥542,048,671.13, up by 9.92% year-over-year[3] - The company's operating income for the year-to-date reached ¥4,951,543,979.15, a significant increase of 62.53% year-over-year, driven by growth in imported albumin sales[6] - Total revenue for the current period reached ¥4,951,543,979.15, a significant increase from ¥3,046,522,817.78 in the previous period, representing a growth of approximately 62.5%[15] - Operating profit for the current period was ¥1,900,857,794.52, compared to ¥1,588,850,419.93 in the previous period, indicating an increase of about 19.6%[16] - Net profit attributable to shareholders of the parent company was ¥1,603,811,643.64, up from ¥1,396,174,488.18, reflecting a growth of approximately 14.9%[16] - The comprehensive income attributable to the parent company for the current period was ¥3,072,458,542.24, compared to ¥1,305,441,786.15 in the same period last year[17] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥30,228,237,255.47, reflecting a 10.98% increase from the end of the previous year[3] - Total assets increased to ¥30,228,237,255.47 from ¥27,236,582,048.82, marking a rise of about 11.6%[15] - Non-current assets totaled ¥22,287,466,066.89, up from ¥20,364,331,133.06, which is an increase of approximately 9.4%[15] - Current liabilities rose to ¥1,422,394,257.08 from ¥1,306,625,745.51, representing an increase of about 8.9%[15] - Total liabilities increased to ¥1,422,394,257.08 from ¥1,306,625,745.51, indicating a rise of about 8.9%[34] - The total equity attributable to shareholders of the parent company rose to ¥28,786,765,664.31 from ¥25,902,445,517.58, indicating an increase of approximately 11.1%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,203,356,366.64, showing a slight increase of 1.96% compared to the previous year[3] - The company's cash and cash equivalents as of September 30, 2022, amounted to approximately ¥3.17 billion, an increase from ¥2.75 billion at the beginning of the year[13] - The company reported a net cash increase of ¥-68,862,752.42 in cash and cash equivalents for the current period[19] - The net increase in cash and cash equivalents was CNY -68,862,752.42, compared to a positive increase of CNY 159,074,397.72 in the prior year, indicating liquidity challenges[39] Shareholder Information - The total number of common shareholders at the end of the reporting period was 121,818[7] - GRIFOLS, S.A. is the largest shareholder, holding 26.20% of shares, equivalent to 1,766,165,808 shares[7] - The second largest shareholder, RAAS CHINA LIMITED, holds 5.83% of shares, totaling 392,878,676 shares[7] Research and Development - Research and development expenses increased by 31.32% to ¥102,089,434.95, indicating a focus on enhancing project development[6] - Research and development expenses for the current period were ¥102,089,434.95, compared to ¥77,743,274.40 in the previous period, showing an increase of approximately 31.3%[16] Operating Costs - The company experienced a 93.00% increase in operating costs, amounting to ¥2,716,933,294.97, largely due to the higher proportion of imported albumin sales[6] - The total operating costs for the current period were ¥3,352,262,703.29, up from ¥1,899,585,559.02, indicating an increase of about 76.7%[36] Other Financial Metrics - The company's basic earnings per share for the period was ¥0.081, a 12.50% increase compared to the same period last year[3] - The company's weighted average return on net assets was 5.86%, an increase of 0.43 percentage points year-on-year[23] - Other comprehensive income after tax for the current period was ¥1,468,646,898.60, a significant improvement from -¥90,732,702.03 in the previous period[16]